Why did 2181.HK stock fall so sharply today?

2181.HK stock fell **-25.00%** on 18 Mar 2026 on heavier-than-normal selling ahead of earnings and because traders priced in risk around late-stage clinical readouts. Volume of **412,000** versus average **544,771** suggests position unwinding rather than normal liquidity-driven selling.

What is the Meyka AI forecast for 2181.HK stock?

Meyka AI's forecast model projects **monthly HKD 0.75**, **quarterly HKD 0.63**, and **yearly HKD 0.70**. The one-year projection implies about **+30.12%** upside from HKD 0.54. Forecasts are model-based projections and not guarantees.

What are the main risks investors should monitor for 2181.HK stock?

Key risks are clinical trial setbacks, weaker-than-expected earnings, high debt-to-equity (**3.09**), stretched inventory days (**923**), and valuation gaps vs sector averages. Any negative regulatory or licensing update can trigger further downside.

Should I trade 2181.HK stock before the earnings release?

Trading before earnings is higher risk. Liquidity and volatility are elevated. Short-term traders should size positions carefully and use stop-losses. Wait for clearer trial or earnings outcomes if you prefer lower risk exposure.

HK Stocks

Mabpharm (2181.HK) HKSE down 25% on 18 Mar 2026: earnings and trials in focus

ByHuzaifa Zahoor March 18, 2026March 18, 2026

2181.HK stock plunged -25.00% to HKD 0.54 at close on 18 Mar 2026 on the Hong Kong Stock Exchange (HKSE). Trading volume reached 412,000 shares versus an average of 544,771, signaling outsized selling pressure. The move came ahead of a scheduled earnings announcement on 26 Mar 2026 and amid an active clinical pipeline. We examine price drivers, balance sheet signals, technicals, and Meyka AI model forecasts to frame the near-term outlook for Mabpharm Limited (2181.HK) in Hong Kong